Scarica l'app Stockscreener
60.43
3.30%
1.9236
Precedente Chiudi:
$58.51
Aprire:
$58.42
Volume 24 ore:
437.73K
Relative Volume:
0.32
Capitalizzazione di mercato:
$8.68B
Reddito:
-
Utile/perdita netta:
$-507.65M
Rapporto P/E:
-13.14
EPS:
-4.6
Flusso di cassa netto:
$-616.24M
1 W Prestazione:
+11.72%
1M Prestazione:
+14.62%
6M Prestazione:
+87.18%
1 anno Prestazione:
-24.20%
Intervallo 1D:
$58.16
$61.25
Intervallo di 1 settimana:
$52.86
$61.25
Portata 52W:
$27.66
$83.33
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
60.45 | 8.40B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.75 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.78 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.95 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Reiterato | Needham | Buy |
| 2025-09-12 | Iniziato | Goldman | Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a 74% Potential Upside in the Innovative Vaccine Sector - DirectorsTalk Interviews
Earnings Outlook For Vaxcyte - Benzinga
Aug Movers: Whats the RSI of Vaxcyte Inc stockRisk Management & Safe Entry Trade Signal Reports - baoquankhu1.vn
Volume Report: Is Vaxcyte Inc affected by consumer sentiment2025 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Aug Retail: What hedge funds are buying MFS High Yield Municipal TrustDividend Hike & AI Powered Market Trend Analysis - baoquankhu1.vn
Technical Analysis: Is PSMT a defensive stockPrice Action & Daily Volume Surge Signals - baoquankhu1.vn
Vaxcyte’s VAX-31 Moves Into Phase 3: What This Pneumococcal Vaccine Update Means for PCVX Investors - TipRanks
Vaxcyte shows market leadership with jump to 85 RS rating - MSN
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials - Finviz
Vaxcyte (PCVX) $632.5M stock offering follows bullish Cantor Fitzgerald rating - MSN
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating - Finviz
Vaxcyte (PCVX) price target increased by 19.72% to 99.96 - MSN
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) - Bitget
Should Vaxcyte’s OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors? - Yahoo Finance
Precision Trading with Vaxcyte Inc. (PCVX) Risk Zones - Stock Traders Daily
Nasdaq Moves: What is the target price for Vaxcyte Inc. stockEarnings Overview Summary & Verified Short-Term Plans - mfd.ru
Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech Summit - MarketBeat
Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - marketscreener.com
Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm
Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq
Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily
Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - The Globe and Mail
Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance
Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network
Vaxcyte Closes Public Offering of Shares - marketscreener.com
Vaxcyte closes $632.5 million public offering of common stock - Investing.com
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
0.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):